MBOT
Microbot Medical Inc. NASDAQ Listed Mar 25, 1992$2.14
After hrs
$2.19
+0.00%
Mkt Cap $97.5M
52w Low $1.60
17.6% of range
52w High $4.67
50d MA $2.40
200d MA $2.54
P/E (TTM)
-7.2x
EV/EBITDA
-6.0x
P/B
1.2x
Debt/Equity
0.0x
ROE
-17.0%
P/FCF
-7.0x
RSI (14)
—
ATR (14)
—
Beta
1.19
50d MA
$2.40
200d MA
$2.54
Avg Volume
2.1M
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
25 Recreation Park Drive · Hingham, MA 02043 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.06 | -0.04 | +33.3% | 2.62 | -1.9% | -8.8% | -3.8% | +4.8% | -1.7% | +1.3% | — |
| Nov 12, 2025 | AMC | -0.06 | -0.07 | -16.7% | 2.12 | -1.9% | -6.1% | +4.0% | -2.4% | -1.0% | -4.0% | — |
| Aug 12, 2025 | AMC | -0.08 | -0.10 | -25.0% | 3.12 | +0.0% | -2.6% | +3.0% | -1.3% | -0.3% | +0.3% | — |
| May 14, 2025 | AMC | -0.13 | -0.08 | +38.5% | 2.46 | +1.6% | +8.5% | +0.4% | +2.2% | -4.4% | -3.1% | — |
| Mar 25, 2025 | AMC | -0.18 | -0.20 | -11.1% | 1.59 | +0.6% | -4.4% | +0.7% | -4.6% | +3.4% | -1.3% | — |
| Nov 13, 2024 | AMC | -0.17 | -0.20 | -17.6% | 1.00 | -0.7% | -4.7% | -2.4% | -2.6% | +2.4% | -0.4% | — |
| Aug 14, 2024 | AMC | -0.17 | -0.17 | +0.0% | 0.99 | +1.0% | +1.0% | +2.0% | +1.0% | +0.0% | +1.0% | — |
| May 15, 2024 | AMC | -0.17 | -0.17 | +0.0% | 0.93 | -0.0% | +4.0% | -2.8% | +6.3% | -1.0% | +9.1% | — |
| Mar 27, 2024 | AMC | -0.25 | -0.26 | -4.0% | 1.15 | -1.7% | +7.0% | +8.1% | -8.3% | +3.3% | +0.0% | — |
| Nov 14, 2023 | AMC | -0.25 | -0.21 | +16.0% | 1.39 | +0.4% | +2.5% | -4.9% | +2.2% | -0.7% | -1.5% | — |
| Aug 14, 2023 | AMC | -0.31 | -0.25 | +19.4% | 2.08 | -1.0% | +2.4% | -2.8% | +0.0% | -2.4% | +2.5% | — |
| Mar 31, 2023 | AMC | -0.45 | -0.38 | +15.6% | 2.08 | +0.5% | +0.0% | -5.3% | -2.0% | -2.6% | +2.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.35 | $2.41 | +2.6% | +3.4% | -1.6% | +0.0% | -2.1% | -1.7% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.29 | $2.46 | +7.4% | +5.7% | -6.6% | -2.2% | +12.7% | -1.2% |
| Oct 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.88 | $2.96 | +2.8% | +1.4% | -2.7% | -2.8% | +1.4% | -4.6% |
| Sep 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.57 | $3.64 | +2.0% | +9.0% | +4.1% | -15.6% | -2.3% | -0.6% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.65 | $1.70 | +3.0% | +8.5% | +24.6% | +2.2% | +11.8% | -3.5% |
| Jan 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.91 | $2.02 | +5.8% | +6.3% | -1.5% | -3.5% | -6.7% | +2.8% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.00 | $1.20 | +20.0% | +38.0% | -17.4% | +1.8% | -0.9% | -6.1% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.03 | $1.03 | +0.0% | -7.9% | -5.1% | -1.1% | -2.8% | +2.6% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.46 | $1.42 | -2.7% | +0.0% | -7.5% | -1.5% | -4.9% | -0.4% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.43 | $3.43 | +0.0% | +0.6% | -16.8% | +2.1% | -1.4% | -5.9% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.02 | $2.00 | -1.0% | +10.4% | +18.8% | +0.4% | -1.9% | +0.0% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.15 | $1.15 | +0.0% | -4.3% | -3.6% | +0.9% | +12.1% | +0.0% |
| Nov 25 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $7.25 | $7.47 | +3.0% | +0.3% | +1.2% | +10.6% | -6.3% | -0.7% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.25 | $7.47 | +3.0% | +0.3% | +1.2% | +10.6% | -6.3% | -0.7% |
| Nov 25 | H.C. Wainwright | Maintains | Buy → Buy | — | $7.25 | $7.47 | +3.0% | +0.3% | +1.2% | +10.6% | -6.3% | -0.7% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.27 | $10.09 | -1.8% | -8.7% | -11.3% | -6.2% | -10.5% | +3.4% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.17 | $15.30 | +16.2% | -5.2% | -7.1% | +2.9% | +1.8% | +2.7% |
| Jan 13 | H.C. Wainwright | Maintains | Buy → Buy | — | $13.17 | $15.30 | +16.2% | -5.2% | -7.1% | +2.9% | +1.8% | +2.7% |
| Dec 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.11 | $11.79 | +16.6% | +61.0% | -14.0% | -20.7% | -5.0% | -3.6% |
| Dec 24 | H.C. Wainwright | Maintains | Buy → Buy | — | $10.11 | $11.79 | +16.6% | +61.0% | -14.0% | -20.7% | -5.0% | -3.6% |
| Jul 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.03 | $5.49 | +9.1% | +5.0% | +31.6% | +5.0% | -5.3% | -3.0% |
| Jul 22 | H.C. Wainwright | Maintains | Buy → Buy | — | $5.03 | $5.49 | +9.1% | +5.0% | +31.6% | +5.0% | -5.3% | -3.0% |
| Nov 19 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $3.37 | $3.41 | +1.2% | -12.5% | -20.0% | -8.5% | -1.9% | -13.2% |
| Jan 31 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $15.75 | $16.20 | +2.9% | +0.0% | +2.9% | -3.7% | -1.9% | -11.8% |
No insider trades available.
8-K · 7.01
! Medium
Microbot Medical Inc. -- 8-K 7.01: Regulation FD Disclosure
Microbot Medical disclosed material information via press release that investors should review in the attached exhibit for details on company developments or announcements.
May 5
8-K · 7.01
! Medium
Microbot Medical Inc. -- 8-K 7.01: Regulation FD Disclosure
Microbot Medical is shifting its strategic focus toward U.S. market expansion while building infrastructure for future international growth, signaling confidence in domestic commercial momentum.
Apr 30
8-K · 7.01
! Medium
Microbot Medical, Inc. -- 8-K 7.01: Regulation FD Disclosure
Microbot Medical's LIBERTY robotic system gains potential competitive advantage as revised interventional radiology safety guidelines could strengthen its market positioning with healthcare providers.
Apr 22
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Microbot Medical disclosed material non-public information via press release on April 14, 2026; investors should review the attached disclosure for potential stock-moving developments affecting valuation and trading decisions.
Apr 14
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
The vague 8-K disclosure provides minimal substantive information, leaving investors unable to assess material developments affecting MBOT's regulatory progress or business outlook.
Apr 13
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
MBOT has obtained legal validation for its at-the-market stock offering program, enabling future capital raises that could dilute existing shareholders but provide flexible funding flexibility for operations.
Apr 10
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Microbot Medical's LIBERTY system achieved successful clinical validation at a major healthcare system, potentially opening a significant new market for its robotic endovascular platform and justifying higher valuations based on expanded addressable market prospects.
Mar 26
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Peer-reviewed publication of MBOT's robotic system feasibility study validates technology safety and efficacy, potentially accelerating clinical adoption and reducing regulatory risk for commercialization.
Mar 24
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
I cannot provide an accurate analysis without access to the actual press release and presentation materials referenced in exhibits 99.1 and 99.2, which are the substantive content of this disclosure filing.
Mar 17
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
MBOT's first Oppenheimer conference presentation highlights LIBERTY robotic system adoption progress during limited market release, potentially signaling commercial momentum and analyst awareness that could drive institutional investor interest and stock visibility.
Mar 10
8-K · 7.01
! Medium
Microbot Medical, Inc. -- 8-K 7.01: Regulation FD Disclosure
Microbot Medical disclosed material information to the public via press release, potentially impacting investor understanding of company developments or financial conditions.
Mar 4
8-K · 7.01
! Medium
Microbot Medical, Inc. -- 8-K 7.01: Regulation FD Disclosure
Microbot Medical disclosed material information to investors via press release, though the specific details require reviewing the attached exhibit for investment implications.
Mar 3
8-K · 7.01
! Medium
Microbot Medical, Inc. -- 8-K 7.01: Regulation FD Disclosure
Microbot Medical disclosed material information through a press release but the specific details require reviewing the attached exhibit to assess any impact on investors' holdings.
Feb 24
8-K · 5.02
!!! Very High
Microbot Medical, Inc. -- 8-K 5.02: Executive Change
Microbot Medical's new employment agreement with an executive beginning in fiscal 2026 includes annual salary reviews tied to performance metrics, potentially affecting compensation costs and shareholder value.
Feb 24
8-K · 7.01
! Medium
Microbot Medical, Inc. -- 8-K 7.01: Regulation FD Disclosure
Microbot Medical disclosed material information via press release under Regulation FD, requiring investors to review the furnished exhibit for details on company developments or announcements.
Feb 19
8-K · 7.01
! Medium
Microbot Medical, Inc. -- 8-K 7.01: Regulation FD Disclosure
Microbot Medical disclosed material information via press release without specifying details in this filing, requiring investors to review the exhibit for the company's latest operational or strategic developments.
Feb 12
8-K · 7.01
! Medium
Microbot Medical, Inc. -- 8-K 7.01: Regulation FD Disclosure
Microbot Medical is presenting physician experiences with its LIBERTY robotic endovascular system during limited market release, demonstrating clinical adoption progress to investors and the market.
Feb 5
Data updated apr 25, 2026 8:50pm
· Source: massive.com